Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients With Systemic Autoimmune Rheumatic Diseases.
J Rheumatol
; 51(3): 305-312, 2024 Mar 01.
Article
in En
| MEDLINE
| ID: mdl-37839812
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Rheumatic Diseases
/
Antirheumatic Agents
/
COVID-19
/
Antibodies, Monoclonal
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Rheumatol
Year:
2024
Type:
Article